Alto Neuroscience, Inc.
Business
Alto Neuroscience is a clinical-stage biopharmaceutical company developing personalized psychiatry treatments using its proprietary Precision Psychiatry Platform to identify brain-based biomarkers for patient selection. The company's pipeline includes seven clinical-stage product candidates addressing major depressive disorder, bipolar depression, treatment-resistant depression, schizophrenia, and Parkinson's disease, with ALTO-207 as its most advanced program. Alto develops and advances its candidates through clinical trials globally, leveraging internal clinical operations and software expertise while relying on third-party contract manufacturers and potential strategic partnerships for commercialization.
Summary from 10-K filed 2026-03-16
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 |
|---|---|---|---|---|
| Research and development | 46 | 47 | 30 | |
| General and administrative | 21 | 22 | 8 | |
| Total operating expenses | 66 | 69 | 38 | |
| Loss from operations | −66 | −69 | −38 | |
| Interest income | 7 | 9 | 2 | |
| Interest expense | −2 | −1 | −1 | |
| Loss on debt extinguishment | −681,000 | 0 | — | |
| Other, net | −327,000 | −297,000 | 525,000 | |
| Total other income, net | 3 | 7 | 2 | |
| Net loss | −63 | −61 | −36 | |
| Change in fair value attributable to instrument specific credit risk | 153,000 | 0 | — | |
| Foreign currency translation | −30,000 | −22,000 | −33,000 | |
| Total other comprehensive income (loss) | 123,000 | −22,000 | −33,000 | |
| Comprehensive loss | −63 | −61 | −36 | |
| Net loss per share attributable to common stockholders, basic (in dollars per share) | −2.19 | −2.5 | −9.73 | |
| Net loss per share attributable to common stockholders, diluted (in dollars per share) | −2.19 | −2.5 | −9.73 | |
| Weighted-average number of common shares outstanding, basic (in shares) | 29 | 25 | 4 | |
| Weighted-average number of common shares outstanding, diluted (in shares) | 29 | 25 | 4 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2024 2024-09-30 | FY 2024 2024-08-31 | FY 2023 2023-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 177 | 168 | — | — | 83 | |
| Prepaid expenses and other current assets | 1 | 1 | — | — | 3 | |
| Total current assets | 178 | 169 | — | — | 85 | |
| Restricted cash | 500,000 | 500,000 | — | — | 0 | |
| Property and equipment, net | 2 | 3 | — | — | 1 | |
| Operating right-of-use asset | 4 | 5 | 5 | 5 | 0 | |
| Other assets | 338,000 | 4,000 | — | — | 131,000 | |
| Total assets | 185 | 178 | — | — | 87 | |
| Accounts payable | 2 | 2 | — | — | 1 | |
| Accrued expenses and other current liabilities | 9 | 8 | — | — | 5 | |
| Term loan, current | 585,000 | 0 | — | — | — | |
| Total current liabilities | 11 | 10 | — | — | 6 | |
| Term loan, non-current | 16 | 10 | — | — | 10 | |
| Convertible Grant Agreement | 2 | 1 | — | — | 0 | |
| Lease liability, long-term | 4 | 5 | — | — | 0 | |
| Total liabilities | 34 | 26 | — | — | 17 | |
| Commitments and contingencies (Note 15) | — | — | — | — | — | |
| Common stock (par value $0.0001), 500,000 shares authorized; 31,924 and 26,987 shares issued and outstanding as of December 31, 2025 and 2024 | 3,000 | 3,000 | — | — | 0 | |
| Additional paid-in capital | 353 | 290 | — | — | 5 | |
| Accumulated deficit | −202 | −138 | — | — | −77 | |
| Accumulated other comprehensive loss | 22,000 | −101,000 | — | — | −79,000 | |
| Total stockholders equity | 151 | 151 | — | — | −72 | |
| Total liabilities and stockholders equity | 185 | 178 | — | — | 87 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 |
|---|---|---|---|---|
| Stock-based compensation expense | 8 | 8 | 3 | |
| Depreciation | 700,000 | 500,000 | — | |
| Non-cash research and development license expense | 0 | 735,000 | 0 | |
| Non-cash lease expense | 774,000 | 337,000 | 280,000 | |
| Non-cash interest expense related to term loan | 729,000 | 393,000 | 396,000 | |
| Loss on disposal of assets | 156,000 | 52,000 | 140,000 | |
| Other | 327,000 | 297,000 | — | |
| Prepaid expenses and other assets | 101,000 | −463,000 | 291,000 | |
| Accounts payable | 221,000 | 516,000 | −632,000 | |
| Accrued liabilities and other liabilities | −289,000 | 4 | −357,000 | |
| Net cash used in operating activities | −52 | −47 | −33 | |
| Capital expenditures | −24,000 | −2 | −470,000 | |
| Net cash used in investing activities | −24,000 | −2 | −470,000 | |
| Proceeds from sale of common stock and pre-funded warrants in private placement | 50 | 0 | — | |
| Payments from sale of common stock and pre-funded warrants in private placement | −167,000 | 0 | — | |
| Proceeds from issuance of common stock from initial public offering | 0 | 138 | 0 | |
| Payments on issuance cost from registration statement | −556,000 | 0 | — | |
| Proceeds from issuance of term loan, net | 20 | 0 | — | |
| Repayment of former term loan | −10 | 0 | — | |
| Payment of loan financing cost | −127,000 | 0 | — | |
| Proceeds from Convertible Grant Agreement | 750,000 | 1 | 0 | |
| Proceeds from exercise of stock options | 703,000 | 187,000 | 181,000 | |
| Net cash provided by financing activities | 60 | 136 | 68 | |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | −30,000 | −11,000 | −8,000 | |
| Net increase in cash, cash equivalents and restricted cash | 8 | 86 | 34 | |
| Conversion of K2 term loan into shares of common stock | 4 | 0 | — | |
| Costs from sale of common stock and pre-funded warrants in private placement not yet paid | 107,000 | 0 | — | |
| Conversion of preferred stock into common stock upon completion of initial public offering | 0 | 141 | 0 | |
| Reclassification of preferred warrant liability to equity | 0 | 2 | 0 | |
| Reclassification of deferred offering costs to equity | 0 | 1 | 0 | |
| Operating right-of-use asset obtained in exchange for lease obligation | 0 | 5 | 0 | |
| Deferred offering and share issue costs not yet paid | 0 | 8,000 | 916,000 | |
| Cash paid for interest | 2 | 999,000 | 912,000 |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Alto Neuroscience, Inc.'s CIK number?
Alto Neuroscience, Inc.'s SEC CIK number is 0001999480 (1999480). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Alto Neuroscience, Inc.'s SEC filings?
All of Alto Neuroscience, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Alto Neuroscience, Inc. last report earnings?
Alto Neuroscience, Inc. (ANRO) most recently filed an earnings 8-K with the SEC on Jul 13, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001104659-26-082875). This is Alto Neuroscience, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Alto Neuroscience, Inc.'s most recent earnings 8-K?
Alto Neuroscience, Inc.'s latest earnings 8-K (Item 2.02) was filed Jul 13, 2026 under accession 0001104659-26-082875. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Alto Neuroscience, Inc.'s latest earnings 8-K →
Look up any company's CIK number →